PHASE II STUDY TO ASSESS THE SAFETY AND EFFICACY OF THE CLEVER-1 ANTIBODY BEXMARILIMAB IN COMBINATION WITH PD-1 BLOCKADE IN PATIENTS WITH ADVANCED SOLID TUMORS - BEXCOMBO

被引：0

作者：

Bono, Petri ^{[1
]}

Jalkanen, Juho ^{[2
]}

Pawlitzky, Inka ^{[2
]}

Fjaellskog, Marie-Louise ^{[3
]}

Ahlin, Cecilia ^{[3
]}

机构：

[1] Univ Helsinki, Helsinki, Finland

[2] Faron Ldt, Turku, Finland

[3] Faron, Boston, MA USA

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷

关键词：

D O I：

10.1136/jitc-2022-SITC2022.0709

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

709

引用

页码：A742 / A742

页数：1

共 50 条

[41] Trial in Progress: A Phase I/II Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination with Standard of Care in Patients with Hematological Malignancies (BEXMAB)
Pawlitzky, Inka
Siitonen, Timo
Daver, Naval
Jalkanen, Juho
Aako, Sofia
Fjallskog, Marie-Louise
Kontro, Mika
BLOOD, 2022, 140 : 11751 - 11752
[42] A PHASE 1 STUDY OF SERPLULIMAB (A NOVEL ANTI-PD-1 ANTIBODY) IN COMBINATION WITH HLX04 (AN ANTI-VEGF ANTIBODY) IN PATIENTS WITH ADVANCED SOLID TUMORS.
Guo, Y.
Li, J.
Li, Q.
Xue, J.
Xue, L.
Ge, X.
Lin, F.
Zhao, W.
Tang, W.
Peng, D.
Wang, Q.
Zhu, J.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S29 - S30
[43] A phase 1/2 study of onatasertib, a dual TORC1/2 inhibitor, combined with the PD-1 antibody toripalimab in patients with advanced solid tumors (TORCH-2)
Shu, Pei
Li, Xiaoyu
Yuan, Li
Xie, Hui
Zhou, Qi
Wang, Yongsheng
Li, Qiu
Zheng, Li
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[44] A phase II study to evaluate safety and efficacy of PD-1 blockade plus anti-EGFR target therapy plus chemotherapy in patients with advanced penile squamous cell carcinoma
Shi, Y.
An, X.
Yan, R.
Yao, K.
Xue, C.
Guo, S.
Liu, T.
Li, J.
Ma, H.
Tian, L.
Zhou, F.
Shi, Y.
Han, H.
EUROPEAN UROLOGY, 2021, 79 : S933 - S933
[45] Next-generation immunotherapy for solid tumors: combination immunotherapy with crosstalk blockade of TGFβ and PD-1/PD-L1
Quach, Hue Tu
Hou, Zhaohua
Bellis, Rebecca Y. Y.
Saini, Jasmeen K. K.
Amador-Molina, Alfredo
Adusumilli, Prasad S. S.
Xiong, Yuquan
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2022, 31 (11) : 1187 - 1202
[46] A phase 1 study of MEDI4736, an anti PD-L1 antibody, in patients with advanced solid tumors.
Lutzky, Jose
Antonia, Scott Joseph
Blake-Haskins, Andy
Li, Xia
Robbins, Paul B.
Shaiabl, Aiman M.
Vasseill, Jim
Ibrahim, Ramy A.
Khleif, Samir
Segal, Neil Howard
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[47] A phase 1 study of IMC-001, novel anti-PD-L1 antibody, in patients with advanced solid tumors
Keam, Bhumsuk
Kim, Tae Min
Oh, Do-Youn
Ock, Chan-Young
Kang, Won Ki
Park, Yeon Hee
Lee, Jeeyun
Lee, Ji Hye
Song, Yun Jeong
Park, Young Suk
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[48] A phase 1 study of serplulimab, a novel humanized monoclonal anti-PD-1 antibody, in patients with advanced solid tumors.
Ho, Ching-Liang
Chao, Tsu-Yi
Chang, Chia Lun
Lin, Hsuan-Yu
Yang, Futang
Wang, Qingyu
Zhu, Jun
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[49] Phase 1b study to assess the safety, tolerability, and clinical activity of pamiparib in combination with temozolomide in patients with locally advanced or metastatic solid tumors
Stradella, Agostina
Johnson, Melissa
Goel, Sanjay
Park, Haeseong
Lakhani, Nehal
Arkenau, Hendrik-Tobias
Galsky, Matthew D.
Calvo, Emiliano
Baz, Vicente
Moreno, Victor
Saavedra, Omar
Luen, Stephen J.
Mu, Song
Wan, Qiting
Chang, Victoria
Zhang, Wa
Barve, Minal
CANCER MEDICINE, 2024, 13 (13):
[50] A phase 1/2 study of REGN7075 in combination with cemiplimab (cemi) in patients (pts) with advanced solid tumors: Efficacy and safety results
Segal, Neil Howard
Girda, Eugenia
Sohal, Davendra
Lakhani, Nehal J.
Olszanski, Anthony J.
Fong, Lawrence
Kinnaman, Michael David
Han, Hyunsil
Skokos, Dimitris
Casey, Kerry A.
Wang, JuAn
Wang, Bei
Hao, Yi
Li, Siyu
Ganguly, Samit
Lowy, Israel
Seebach, Frank A.
Mathias, Melissa Divya
Johnson, Melissa Lynne
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

← 1 2 3 4 5 →